

## Datasheet

### SARS-CoV-2 S1-Receptor-Binding Domain (RBD) – Delta (B.1.617.2)\_HEK

#### Description:


A recombinant form of the Spike protein receptor binding domain (RBD) from the SARS-CoV-2 Delta variant (B.1.617.2), which is produced under serum-free conditions in human embryonic kidney, HEK293 cells.

#### RBD-Delta (B.1.617.2) variant; containing mutations L452R and T478K.

Protein design and manufacturing process is based on RBD protein (aa 319-541). The protein includes a C-terminal hexa-histidine-tag and is purified using immobilized metal exchange chromatography (IMAC) and preparative SEC (for polishing).

<b>Product Code:</b>	BSV-COV-PR-98HEK
<b>Expression System:</b>	Mammalian; HEK
<b>Protein Accession Number:</b>	QHD43416.1 (GenBank)
<b>Amino Acids:</b>	319-541
<b>Mutations:</b>	L452R, T478K
<b>Mature Protein N-Term:</b>	Arg319 (Predicted)
<b>Tag:</b>	6 x His-Tag; C-terminal
<b>Expected Molecular Weight:</b>	26 kDa (glycosylated form runs at 25-40 kDa in gel electrophoresis)
<b>Formulation:</b>	Liquid, 20 mM NaPP, 300 mM NaCl pH 7.2
<b>Concentration:</b>	> 0.5 mg/ml
<b>Purity:</b>	> 90% (via analytical CGE under reducing conditions)

**The product is for further research use or manufacturing only.**



**SARS-CoV-2 receptor-binding domains (RBD-Wuhan, Delta, Delta plus, Lambda, Eta and Mu) recombinantly expressed in HEK cells tested as solid phase bound capture antigens at 2 µg/mL in an in-house SARS-CoV-2 IgG ELISA.**

14 SARS-CoV-2 positive patient serum samples (obtained before October 2020) were applied. The line indicates the median of the absorbance values.